A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung

• Published in: Journal of cystic fibrosis Vol. 21; no. 6; pp. 996 - 1005
• Main Authors: Sosinski, Lo M., H, Christian Martin, Neugebauer, Kerri A., Ghuneim, Lydia-Ann J., Guzior, Douglas V., Castillo-Bahena, Alicia, Mielke, Jenna, Thomas, Ryan, McClelland, Marc, Conrad, Doug, Quinn, Robert A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2022
• Subjects: Aminophenols - therapeutic use; Benzodioxoles - therapeutic use; Cystic Fibrosis; Cystic Fibrosis - genetics; Cystic Fibrosis Transmembrane Conductance Regulator - genetics; Humans; Lung - metabolism; Metabolome; Microbiome; Microbiota; Pulmonary/Respiratory; RNA, Ribosomal, 16S - genetics; Sputum; Trikafta; Metabolome; Cystic Fibrosis; Trikafta; Sputum; Microbiome
• ISSN: 1569-1993; 1873-5010; 1873-5010
• DOI: 10.1016/j.jcf.2021.11.003

•Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy alters the microbiome and metabolome of lung sputum within the first year of therapy•Alpha-diversity of the microbiome increased, and the metabolome becomes highly varied across subjects while on therapy•No single bacterium was significantly different...